
Akebia Therapeutics, Inc.: shareholders and insiders
Price
$0.42
November 19, 2026Market cap $112M
What Ploutos Investor adds for Akebia Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Aug 10, 2026, from their own Form 4 filings.
Bought on the market
$86.6K
1 person
Sold on the market
$963.0K
6 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $86.6K by 1 person·sold $963.0K by 6 people
- 2025: no buys, no sales
- 2026: bought $86.6K by 1 person, sold $963.0K by 6 people
- Aug 6, 2026John P. ButlerCEO and PresidentKind
- Jun 29, 2026Erik OstrowskiSVP, CFO, CBO & TreasurerKind10b5-1
- Jun 17, 2026Myles WolfDirectorKind
- Jun 17, 2026Cynthia SmithDirectorKind
- Jun 17, 2026Michael W RogersDirectorKind
- Jun 17, 2026Ron FriesonDirectorKind
- Jun 17, 2026Leanne M ZumwaltDirectorKind
- Jun 17, 2026Adrian AdamsDirectorKind
- Mar 4, 2026John P. ButlerCEO and PresidentKind
- Feb 2, 2026John P. ButlerCEO and PresidentKind10b5-1
- Feb 2, 2026John P. ButlerCEO and PresidentKind10b5-1
- Feb 2, 2026John P. ButlerCEO and PresidentKind10b5-1
- Feb 2, 2026John P. ButlerCEO and PresidentKind10b5-1
- Feb 2, 2026Steven Keith BurkeSVP, Chief Medical OfficerKind10b5-1
- Feb 2, 2026Steven Keith BurkeSVP, Chief Medical OfficerKind10b5-1
- Feb 2, 2026Steven Keith BurkeSVP, Chief Medical OfficerKind10b5-1
- Feb 2, 2026Nicholas GrundChief Commercial OfficerKind10b5-1
- Feb 2, 2026Nicholas GrundChief Commercial OfficerKind10b5-1
- Feb 2, 2026Erik OstrowskiSVP, CFO, CBO & TreasurerKind10b5-1
- Feb 2, 2026Richard C MalabreSVP, Chief Accounting OfficerKind10b5-1
- Feb 2, 2026Richard C MalabreSVP, Chief Accounting OfficerKind10b5-1
- Feb 2, 2026Carolyn M. RucciSVP, Chief Legal OfficerKind10b5-1
- Feb 2, 2026Carolyn M. RucciSVP, Chief Legal OfficerKind10b5-1
- Feb 2, 2026Carolyn M. RucciSVP, Chief Legal OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | John P. ButlerCEO and President | 350.0K | $0.63 | $220.5K | Form 4 | |
| Jun 29, 2026 | Erik OstrowskiSVP, CFO, CBO & Treasurer | 10b5-1 | 56.0K | $1.11 | $62.2K | Form 4 |
| Jun 17, 2026 | Myles WolfDirector | 35.7K | – | – | Form 4 | |
| Jun 17, 2026 | Cynthia SmithDirector | 35.7K | – | – | Form 4 | |
| Jun 17, 2026 | Michael W RogersDirector | 35.7K | – | – | Form 4 | |
| Jun 17, 2026 | Ron FriesonDirector | 35.7K | – | – | Form 4 | |
| Jun 17, 2026 | Leanne M ZumwaltDirector | 35.7K | – | – | Form 4 | |
| Jun 17, 2026 | Adrian AdamsDirector | 35.7K | – | – | Form 4 | |
| Mar 4, 2026 | John P. ButlerCEO and President | 69.3K | $1.25 | $86.6K | Form 4 | |
| Feb 2, 2026 | John P. ButlerCEO and President | 10b5-1 | 46.7K | $1.39 | $64.9K | Form 4 |
| Feb 2, 2026 | John P. ButlerCEO and President | 10b5-1 | 96.1K | $1.39 | $133.5K | Form 4 |
| Feb 2, 2026 | John P. ButlerCEO and President | 10b5-1 | 114.9K | $1.39 | $159.7K | Form 4 |
| Feb 2, 2026 | John P. ButlerCEO and President | 10b5-1 | 83.7K | $1.39 | $116.3K | Form 4 |
| Feb 2, 2026 | Steven Keith BurkeSVP, Chief Medical Officer | 10b5-1 | 20.7K | $1.39 | $28.8K | Form 4 |
| Feb 2, 2026 | Steven Keith BurkeSVP, Chief Medical Officer | 10b5-1 | 21.6K | $1.39 | $30.0K | Form 4 |
| Feb 2, 2026 | Steven Keith BurkeSVP, Chief Medical Officer | 10b5-1 | 25.4K | $1.39 | $35.3K | Form 4 |
| Feb 2, 2026 | Nicholas GrundChief Commercial Officer | 10b5-1 | 31.2K | $1.39 | $43.4K | Form 4 |
| Feb 2, 2026 | Nicholas GrundChief Commercial Officer | 10b5-1 | 53.6K | $1.39 | $74.5K | Form 4 |
| Feb 2, 2026 | Erik OstrowskiSVP, CFO, CBO & Treasurer | 10b5-1 | 35.0K | $1.39 | $48.6K | Form 4 |
| Feb 2, 2026 | Richard C MalabreSVP, Chief Accounting Officer | 10b5-1 | 36.1K | $1.39 | $50.2K | Form 4 |
| Feb 2, 2026 | Richard C MalabreSVP, Chief Accounting Officer | 10b5-1 | 13.4K | $1.39 | $18.6K | Form 4 |
| Feb 2, 2026 | Carolyn M. RucciSVP, Chief Legal Officer | 10b5-1 | 27.5K | $1.39 | $38.3K | Form 4 |
| Feb 2, 2026 | Carolyn M. RucciSVP, Chief Legal Officer | 10b5-1 | 25.4K | $1.39 | $35.3K | Form 4 |
| Feb 2, 2026 | Carolyn M. RucciSVP, Chief Legal Officer | 10b5-1 | 16.8K | $1.39 | $23.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by AKBA's officers and directors from 2014 up to November 18, 2025, 12 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 7 more, back to 2014
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class7.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.20% | 19.22M | Jan 21, 20262 filings since Apr 17, 2025 | 13G/A |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-39%
- Millennium Mgmt (Englander)In the quarter-44%
- D.E. ShawIn the quarter-75%
- Renaissance TechnologiesIn the quarter+54%
- AQR CapitalIn the quarter-31%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 1.33M | $1.2M | 0.00% | |
| Citadel Advisors (Griffin) | 1.04M | -39% | $1.0M | 0.00% |
| Millennium Mgmt (Englander) | 1.79M | -44% | $1.6M | 0.00% |
| D.E. Shaw | 21.7K | -75% | $0 | 0.00% |
| Renaissance Technologies | 1.88M | +54% | $1.7M | 0.00% |
| AQR Capital | 6.29M | -31% | $5.8M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.61% of its shares outstanding were held short, +2.6% since the report before.
- Shares held short
- 23.07M
- 8.61%
- Since the report before22.48M on Sep 30, 2026
- +2.6%
- 3.0
- 7.79M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 34%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 10.32M
- Nov 15, 2023: Shares held short 9.88M
- Nov 30, 2023: Shares held short 9.01M
- Dec 15, 2023: Shares held short 7.33M
- Dec 29, 2023: Shares held short 7.87M
- Jan 12, 2024: Shares held short 7.83M
- Jan 31, 2024: Shares held short 8.78M
- Feb 15, 2024: Shares held short 8.00M
- Feb 29, 2024: Shares held short 8.11M
- Mar 15, 2024: Shares held short 10.13M
- Mar 28, 2024: Shares held short 13.40M
- Apr 15, 2024: Shares held short 13.69M
- Apr 30, 2024: Shares held short 11.86M
- May 15, 2024: Shares held short 11.70M
- May 31, 2024: Shares held short 13.16M
- Jun 14, 2024: Shares held short 12.30M
- Jun 28, 2024: Shares held short 13.11M
- Jul 15, 2024: Shares held short 18.66M
- Jul 31, 2024: Shares held short 17.89M
- Aug 15, 2024: Shares held short 18.95M
- Aug 30, 2024: Shares held short 19.07M
- Sep 13, 2024: Shares held short 19.06M
- Sep 30, 2024: Shares held short 18.80M
- Oct 15, 2024: Shares held short 17.68M
- Oct 31, 2024: Shares held short 14.84M
- Nov 15, 2024: Shares held short 11.96M
- Nov 29, 2024: Shares held short 11.56M
- Dec 13, 2024: Shares held short 14.07M
- Dec 31, 2024: Shares held short 16.68M
- Jan 15, 2025: Shares held short 17.99M
- Jan 31, 2025: Shares held short 14.45M
- Feb 14, 2025: Shares held short 14.98M
- Feb 28, 2025: Shares held short 14.88M
- Mar 14, 2025: Shares held short 16.57M
- Mar 31, 2025: Shares held short 17.36M
- Apr 15, 2025: Shares held short 17.92M
- Apr 30, 2025: Shares held short 17.77M
- May 15, 2025: Shares held short 19.72M
- May 30, 2025: Shares held short 20.05M
- Jun 13, 2025: Shares held short 18.50M
- Jun 30, 2025: Shares held short 25.50M
- Jul 15, 2025: Shares held short 25.37M
- Jul 31, 2025: Shares held short 24.54M
- Aug 15, 2025: Shares held short 24.81M
- Aug 29, 2025: Shares held short 27.09M
- Sep 15, 2025: Shares held short 27.36M
- Sep 30, 2025: Shares held short 29.40M
- Oct 15, 2025: Shares held short 29.32M
- Oct 31, 2025: Shares held short 35.52M
- Nov 14, 2025: Shares held short 35.34M
- Nov 28, 2025: Shares held short 35.92M
- Dec 15, 2025: Shares held short 34.58M
- Dec 31, 2025: Shares held short 36.06M
- Jan 15, 2026: Shares held short 37.03M
- Jan 30, 2026: Shares held short 36.93M
- Feb 13, 2026: Shares held short 31.21M
- Feb 27, 2026: Shares held short 29.69M
- Mar 13, 2026: Shares held short 28.99M
- Mar 31, 2026: Shares held short 26.27M
- Apr 15, 2026: Shares held short 27.31M
- Apr 30, 2026: Shares held short 27.62M
- May 15, 2026: Shares held short 26.37M
- May 29, 2026: Shares held short 27.42M
- Jun 15, 2026: Shares held short 29.20M
- Jun 30, 2026: Shares held short 19.18M
- Jul 15, 2026: Shares held short 19.08M
- Jul 31, 2026: Shares held short 19.18M
- Aug 14, 2026: Shares held short 21.37M
- Aug 31, 2026: Shares held short 23.00M
- Sep 15, 2026: Shares held short 20.50M
- Sep 30, 2026: Shares held short 22.48M
- Oct 15, 2026: Shares held short 23.07M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading66.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 66.2% of the shares in the reported trades were short sales, against 61.8% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 66.2%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 61.8%
- Change
- +4.4 pts
- Short sales a dayon average, of 5.33M shares
- 3.53M
- More than atof 3,656 US-listed companies, same days
- 94%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 66%
- Oct 13, 2026: Short sales 64.4%
- Oct 14, 2026: Short sales 52.5%
- Oct 15, 2026: Short sales 52.1%
- Oct 16, 2026: Short sales 54.5%
- Oct 19, 2026: Short sales 54.6%
- Oct 20, 2026: Short sales 58.7%
- Oct 21, 2026: Short sales 73.6%
- Oct 22, 2026: Short sales 67.1%
- Oct 23, 2026: Short sales 62.6%
- Oct 26, 2026: Short sales 54.5%
- Oct 27, 2026: Short sales 65.3%
- Oct 28, 2026: Short sales 67.1%
- Oct 29, 2026: Short sales 66%
- Oct 30, 2026: Short sales 56.3%
- Nov 2, 2026: Short sales 57.2%
- Nov 3, 2026: Short sales 55.5%
- Nov 4, 2026: Short sales 57.6%
- Nov 5, 2026: Short sales 74.4%
- Nov 6, 2026: Short sales 74.2%
- Nov 9, 2026: Short sales 67.1%
- Nov 10, 2026: Short sales 74.6%
- Nov 11, 2026: Short sales 69.6%
- Nov 12, 2026: Short sales 74.7%
- Nov 13, 2026: Short sales 63.1%
- Nov 16, 2026: Short sales 67.8%
- Nov 17, 2026: Short sales 57.6%
- Nov 18, 2026: Short sales 61.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- John P. ButlerCEO and PresidentDirectly3.88M
- Steven Keith BurkeSVP, Chief Medical OfficerDirectly948.4K
- Michel DahanSVP, Chief Operating OfficerDirectly672.1K
- Nicole R. HadasSVP, Chief Legal OfficerDirectly651.2K
- Erik OstrowskiSVP, CFO, CBO & TreasurerDirectly616.6K
- Carolyn M. RucciSVP, Chief Legal OfficerDirectly588.4K
- Nicholas GrundChief Commercial OfficerDirectly561.8K
- Richard C MalabreSVP, Chief Accounting OfficerDirectly312.8K
- Adrian AdamsDirectorDirectly236.2K
- Michael W RogersDirectorDirectly197.4K
- Cynthia SmithDirectorDirectly196.6K
- Myles WolfDirectorDirectly169.1K
- Ron FriesonDirectorDirectly165.2K
- Leanne M ZumwaltDirectorDirectly145.1K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| John P. ButlerCEO and President | 3.88M | – | Aug 6, 2026 | Form 4 |
| Steven Keith BurkeSVP, Chief Medical Officer | 948.4K | – | Feb 2, 2026 | Form 4 |
| Michel DahanSVP, Chief Operating Officer | 672.1K | – | May 13, 2024 | Form 4 |
| Nicole R. HadasSVP, Chief Legal Officer | 651.2K | – | May 13, 2024 | Form 4 |
| Erik OstrowskiSVP, CFO, CBO & Treasurer | 616.6K | – | Jun 29, 2026 | Form 4 |
| Carolyn M. RucciSVP, Chief Legal Officer | 588.4K | – | Feb 2, 2026 | Form 4 |
| Nicholas GrundChief Commercial Officer | 561.8K | – | Feb 2, 2026 | Form 4 |
| Richard C MalabreSVP, Chief Accounting Officer | 312.8K | – | Feb 2, 2026 | Form 4 |
| Adrian AdamsDirector | 236.2K | – | Jun 17, 2026 | Form 4 |
| Michael W RogersDirector | 197.4K | – | Jun 17, 2026 | Form 4 |
| Cynthia SmithDirector | 196.6K | – | Jun 17, 2026 | Form 4 |
| Myles WolfDirector | 169.1K | – | Jun 17, 2026 | Form 4 |
| Ron FriesonDirector | 165.2K | – | Jun 17, 2026 | Form 4 |
| Leanne M ZumwaltDirector | 145.1K | – | Jun 17, 2026 | Form 4 |
A lower bound: it counts only the 14 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.07%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.03%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.00%
- SCHBSchwab U.S. Broad Market ETFWeight in the fund0.00%
13 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 177
- Q4 2025: Managers 166
- Q1 2026: Managers 172
- Q2 2026: Managers 170
Institutional investors by quarter
The fund managers holding AKBA, quarter by quarter, from Q1 2014 to Q2 2025, 46 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 170 managers held 110M shares, worth $125M. During the quarter 37 opened a position, 39 closed one, 66 added and 33 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+6.9%
- Vanguard Capital ManagementIn the quarter+1.4%
- AQR CapitalIn the quarter+411%
- Geode Capital ManagementIn the quarter+4.3%
- State StreetIn the quarter-54%
- Jacobs Levy Equity ManagementIn the quarter+894%
- Acadian Asset ManagementIn the quarter+191%
- Nantahala Capital ManagementIn the quarter+100%
- Goldman Sachs GroupIn the quarter+2.4%
- Millennium Mgmt (Englander)In the quarter+34%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 19.99M | +6.9% | $23M |
| Vanguard Capital Management | 11.32M | +1.4% | $13M |
| AQR Capital | 9.15M | +411% | $10M |
| Geode Capital Management | 6.73M | +4.3% | $7.7M |
| State Street | 5.39M | -54% | $6.1M |
| Jacobs Levy Equity Management | 4.27M | +894% | $4.9M |
| Acadian Asset Management | 4.00M | +191% | $4.6M |
| Nantahala Capital Management | 4.00M | +100% | $4.6M |
| Goldman Sachs Group | 3.69M | +2.4% | $4.2M |
| Millennium Mgmt (Englander) | 3.20M | +34% | $3.6M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Akebia Therapeutics's filings show?
Who buys and sells is one part of Akebia Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have AKBA's insiders bought or sold?
From Jun 22, 2026 to Aug 10, 2026 Akebia Therapeutics's insiders bought 0 and sold $62.2K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold AKBA?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $5.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.